- A groundbreaking study from Israel has documented the superior therapeutic properties of whole plant CBD-rich Cannabis extract as compared to synthetic, single-molecule cannabidiol (CBD).Published in the journal Pharmacology & Pharmacy (Feb. 2015), the article directly challenges one of the sacred cows of Big Pharma and the medical-industrial complex ? the notion that ?crude? botanical preparations are inherently low grade and less effective than pure, single-molecule compounds.Entitled ?Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol,? the article is all the more noteworthy given the contribution of co-author Lumir Hanus, who was instrumental in the discovery of anandamide, the endogenous cannabinoid compound first identified in the mammalian brain in 1992.Hanus and two Israeli colleagues from Hebrew University of Jerusalem surveyed the scientific literature and noted that during the past fifteen years numerous preclinical studies had focused on the anti-inflammatory effects of pure, single-molecule CBD in animal models of various pathologies, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and diabetes. (See preclinical data regarding CBD.)These studies showed that administration of pure, single-molecule CBD resulted in a bell-shaped dose-response curve, meaning that when the amount of CBD exceeded a certain point its therapeutic impact declined dramatically. ?Healing was only observed when CBD was given within a very limited dose range, whereas no beneficial effect was achieved at either lower or higher doses,? the authors observed. This characteristic of single-molecule CBD?manifested as a bell-shaped dose response?imposes serious obstacles that limit its usefulness in a clinical context.The Israeli team sought to determine whether the administration of a whole plant CBD-rich extract would also generate a bell-shaped dose-response curve when administered to mice. Or would cannabidiol extracted from CBD-rich Cannabis avoid this liability? ?The aim of the present study,? the authors explained, ?was to find a CBD source that could eliminate the bell-shaped dose-response of purified CBD.?The scientists obtained a CBD-rich strain called ?Avidekel? from Tikkun Olam, an Israeli medical marijuana producer. Referred to as ?clone 202? in this study, Avidekel has hardly any THC and therefore is not intoxicating. The origins of Avidekel can be traced to Spain, where breeders developed several phenotypes of ?Cannatonic? (as in ?cannabis tonic?), including a strain that measures close to 20 percent CBD by dry weight with almost no intoxicating ingredients. (The same high-yielding CBD-dominant strain is known as ?ACDC? in California.)The Israeli researchers extracted CBD-rich oil from clone 202. The extract?consisting of 17.9 percent CBD, 1.1 percent THC, 1.1 percent cannabichromene (CBC), 0.2 percent cannabigerol (CBG), and ?traces? of cannabinol (CBN) and cannabivarol (CBDV)?was given to mice to evaluate its anti-inflammatory and painkilling effect.For comparative purposes, the scientists administered pure, synthetic CBD to another group of mice and assessed its anti-inflammatory and analgesic properties. They also compared the extent to which single-molecule CBD and whole plant CBD inhibited the production of tumor necrosis factor alpha (TNFa), a systemic inflammatory signaling molecule. Dysregulation of TNF-alpha production has been implicated in several diseases including cancer, Alzheimer?s, clinical depression, and irritable bowel syndrome.The pure CBD tests confirmed the findings of earlier preclinical research. Once again, singe-molecule CBD administration generated a bell-shaped dose-response curve with a narrow therapeutic window.
Source: CBD-Rich Cannabis vs. Single-Molecule CBD ? Project CBD